成都地区11家医院2011~2013年口服降糖药利用分析  

Utilization of Oral Hypoglycemic Drugs in Eleven Hospitals of Chengdu During 2011-2013

作　　者：孙山[1] 樊新星[1] 

机构地区：[1]成都大学附属医院药剂科,成都610081

出　　处：《药物流行病学杂志》2015年第9期551-554,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的：了解成都地区口服降糖药的临床应用情况。方法：采用《医院处方分析》课题中成都地区11家医院2011~2013年口服降糖药的处方数据进行分析。结果：成都地区口服降糖药销售金额呈逐年上升趋势,双胍类一直居3年的榜首,单品种药物方面,2013年瑞格列奈销售金额上升为第1位,其次为阿卡波糖、格列美脲;格列美脲、二甲双胍各年用药频度（DDDs）中均居前3位;二甲双胍DDDs排序呈逐年下降趋势。结论：成都地区11家医院口服降糖药用量呈逐渐上升趋势,其选用药物的经济性较为合理。Objective： To investigate the utilization of oral hypoglycemic drugs in Chengdu area. Methods： The utilization of oral hypoglycemic drugs in 11 hospitals of Chengdu area from 2011 to 2013 were analyzed statistically. Resuits：There was an upward trend in the consumption sum for the oral medications in Chengdu area, and biguanides took up the first place in the list of consumption sum in 3 years. The top one oral hypoglycemic drug in the list of consumption sum was repaglinide in 2013, followed by acarbose, glimepiride. In terms of DDDs, glimepiride and mefformin ranked the top 3 during the 3 years. The rank DDDs of metformin was decreased year by year. Conclusion：The demanded quantity of oral hypoglycemic drugs was increased year by year from 2011 to 2013. The utilization of oral hypoglycemic drugs in Chengdu area was economical.

关 键 词：降糖药 口服 成都 用药频度 药物利用 

分 类 号：F407.7[经济管理—产业经济]